Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2784544 in Patients With Myeloproliferative Neoplasms
NCT01594723Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2012
- Primary completion
- Mar 2015
- Modality
- Orthosteric Ligands
- Countries
- 9
01
Overview
A Phase 2 trial of gandotinib in polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), sponsored by Eli Lilly and Company. Started May 2012; status: active, not recruiting.
02
Drugs
gandotinib
03
Conditions
polycythemia vera (PV)essential thrombocythemia (ET)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01594723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01594723.